Checkpoint Therapeutics gains approval for cosibelimab but faces financial challenges and tough competition. Learn more about ...

Completed enrollment of 5,000 subject Phase 2b NAVIGATE trialSevere flu season enables potential mid-year assessment of ...

Welcome to the CytomX Therapeutics fourth-quarter 2024 and financial results call. Please be advised that today's call is being recorded. I would now like to hand the call over to your host for today, ...

This page features the latest news about the Checkpoint Therapeutics stock. Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Checkpoint, Sonder ...

Checkpoint Therapeutics Stock Performance NASDAQ:CKPT opened at $3.31 on Monday. The firm has a market capitalization of $161.63 million, a price-to-earnings ratio of -1.80 and a beta of 1.36 ...

Completed enrollment of 5,000 subject Phase 2b NAVIGATE trialSevere flu season enables potential mid-year assessment of efficacyClosed $105.0 million financing with new and existing investorsSignifica ...

W illiam Garrett Gray, the Chief Financial Officer of Checkpoint Therapeutics , Inc. (NASDAQ:CKPT), recently sold 74,110 shares of the company’s common stock.The shares were sold at a weighted ...

On Tuesday, H.C. Wainwright maintained its Buy rating and $34.00 stock price target for Checkpoint Therapeutics (NASDAQ:CKPT). This affirmation follows Checkpoint Therapeutics' ...

James F. Oliviero III, the CEO, President, and Director of Checkpoint Therapeutics , Inc. (NASDAQ:CKPT), recently sold shares worth $64,027 in two separate transactions. The company, currently ...

Discontinuation of BEACON-IPF following DSMB and outside expert panel recommendationSOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE ...

Top-line Phase 2/3 data readout for COMPANION-002, evaluating tovecimig (CTX-009 - a DLL4 x VEGF-A bispecific antibody) in patients with biliary ...